SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Sick Visit — Frédéric Chopin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrédéric Chopin
Date of birth1810-03-01
IdentifiersMRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845
Document date1838-06-09
AuthorMatthias Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Sore throat, runny nose, and cough for three days during tuberculosis treatment. [S]

History of Present Illness

Mr. Chopin is a 28-year-old pianist in the fourth week of the continuation phase of rifapentine, moxifloxacin, and isoniazid for cavitary pulmonary tuberculosis, given by video-observed therapy. Three days ago he developed a scratchy throat and a runny, blocked nose, then a mild dry cough; two of his students had colds last week. His temperature at home has been up to 37.7 °C. He is frightened that the tuberculosis is coming back, because the cough is the first he has had in a month. He has no blood in his sputum, no night sweats, and no weight loss; he has gained 1.6 kg since the end of the intensive phase. He has taken every dose on his video calls. He has not taken anything for the cold yet and asked whether zinc lozenges or an antibiotic would help. He has no tendon pain, tingling, rash, yellowing, or dark urine. [S]

ElementDetail
OnsetThree days ago
LocationThroat and nose, with a mild cough
DurationThree days
CharacterScratchy throat, runny and blocked nose, dry cough
SeverityMild; teaching with difficulty
TimingWeek 12 of 17 of tuberculosis treatment
ContextStudents with colds last week
Modifying factorsNothing taken yet; no doses missed
Associated signs and symptomsTemperature up to 37.7 °C; no hemoptysis, night sweats, or weight loss

Review of Systems

SystemResultFinding
ConstitutionalPositiveLow-grade temperature; no night sweats or weight loss
Ears, nose, mouth, and throatPositiveSore throat, runny and blocked nose; no ear pain
RespiratoryPositiveMild dry cough for two days; no blood, breathlessness, or chest pain
GastrointestinalNegativeNo nausea, abdominal pain, or jaundice
MusculoskeletalNegativeNo tendon or joint pain
NeurologicalNegativeNo numbness or tingling in his fingers or feet

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses)Oral route1838-03-20 to 1838-07-16completedS
Moxifloxacin 400 mg tablet, one tablet daily400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours afterOral route1838-03-20 to 1838-07-16completedS
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeksOral route1838-03-20 to 1838-07-16completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg)Oral route1838-03-20 to 1838-05-14completedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1838-03-20 to 1838-07-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1838-06-09Body height170cmS
1838-06-09Body weight53.6kgS
1838-06-09Body mass index (BMI) [Ratio]18.5kg/m2S
1838-06-09Systolic blood pressure108mm[Hg]S
1838-06-09Diastolic blood pressure68mm[Hg]S
1838-06-09Heart rate88/minS
1838-06-09Respiratory rate16/minS
1838-06-09Body temperature37.6CelS
1838-06-09Oxygen saturation in Arterial blood by Pulse oximetry97%S

Physical Exam

Vital signs recorded on 1838-06-09; see the Vital Signs section. [S]

SystemFinding
GeneralTired but well; weight 53.6 kg; temperature 37.6 °C; masked in the waiting room
Ears, nose, and throatNasal mucosa red and swollen with clear discharge; pharynx mildly red without exudate; ear drums normal
NeckSmall, soft, tender anterior lymph nodes
RespiratoryClear, with no crackles or bronchial breathing over the right upper zone
SkinNo rash or jaundice

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and cultureresolvedconfirmed R04.2S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit.
Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic.
Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion.
Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness.

Assessment and Plan

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention (2016)

Follow-up: Message if the cold is not better in a week. End-of-treatment visit after the last dose in July. Next scheduled visit 1838-07-21: end-of-treatment review after 119 doses. [S]